Why BridgeBio Pharma Inc (BBIO) Stock Is Rising
As of 2026-07-17, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 123.33%. Featured in our EPS revision report on 2026-07-09.
Why BBIO Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised BridgeBio Pharma Inc's next-year EPS growth estimate from 124.07% to 124.58% on 2026-07-13.
- ·Current-Year Growth: Projected at 40.50%, supporting the forward estimate revision.
News Context
BridgeBio's stock has risen primarily due to an earnings per share estimate upgrade on July 13, 2026, with analysts boosting next-year EPS growth from 124.07% to 124.58%. This revision appears tied to positive clinical catalysts, including the NDA submission for encaleret in ADH1 and acoramidis demonstrating disease-modifying effects in ATTR-CM, which strengthen the pipeline beyond the approved drug Attruby. The upgrade's momentum has persisted, with the current next-year EPS growth estimate remaining elevated at 123.33%.
Generated 2026-07-17 · news as of 2026-07-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 123.33%
- EPS growth this year
- 40.50%
- EPS next quarter (est)
- -$0.58
- Last price
- $81.38
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 123.33% | 40.50% | -$0.58 | $81.38 |
| 2026-07-16 | 124.58% | 41.24% | -$0.60 | $80.30 |
| 2026-07-15 | 124.58% | 41.23% | -$0.60 | $82.66 |
| 2026-07-14 | 124.58% | 41.23% | -$0.60 | $84.09 |
| 2026-07-13 | 124.58% | 41.23% | -$0.60 | $83.08 |
| 2026-07-12 | 124.07% | 41.19% | -$0.60 | $85.89 |
| 2026-07-09 | 124.07% | 41.19% | -$0.60 | $90.17 |
| 2026-07-08 | 123.84% | 41.29% | -$0.60 | $78.33 |
| 2026-07-07 | 123.84% | 41.29% | -$0.60 | $77.91 |
| 2026-07-06 | 122.45% | 41.74% | -$0.59 | $77.75 |
| 2026-07-05 | 122.45% | 41.74% | -$0.59 | $77.19 |
| 2026-07-02 | 124.92% | 42.66% | -$0.58 | $77.19 |
| 2026-07-01 | 124.93% | 42.66% | -$0.58 | $74.52 |
| 2026-06-30 | 124.93% | 42.66% | -$0.58 | $74.48 |
| 2026-06-29 | 124.92% | 42.66% | -$0.58 | $72.01 |
| 2026-06-28 | 124.92% | 42.66% | -$0.58 | $70.24 |
| 2026-06-25 | 124.92% | 42.66% | -$0.58 | $69.69 |
| 2026-06-24 | 124.92% | 42.66% | -$0.58 | $69.36 |
| 2026-06-23 | 124.92% | 42.66% | -$0.58 | $68.63 |
| 2026-06-22 | 124.92% | 42.66% | -$0.58 | $68.92 |
| 2026-06-21 | 124.92% | 42.66% | -$0.58 | $66.27 |
| 2026-06-18 | 124.92% | 42.66% | -$0.58 | $66.27 |
| 2026-06-17 | 124.92% | 42.66% | -$0.58 | $67.39 |
| 2026-06-16 | 124.92% | 42.66% | -$0.58 | $66.64 |
| 2026-06-15 | 127.10% | 42.24% | -$0.59 | $68.00 |
| 2026-06-14 | 127.10% | 42.24% | -$0.59 | $66.80 |
| 2026-06-11 | 127.10% | 42.24% | -$0.59 | $67.55 |
| 2026-06-10 | 127.10% | 42.24% | -$0.59 | $67.40 |
| 2026-06-09 | 127.10% | 42.24% | -$0.59 | $67.68 |
| 2026-06-08 | 127.10% | 42.24% | -$0.59 | $67.37 |
Reports Featuring BBIO
Recent News
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?Trefis
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst callsThe Fly
- Wall Street's Cardiac Bet: Where Diagnostics Meet the MoneyPR Newswire
- BridgeBios Attruby challenges Pfizers Vyndamax legacy in pivotal ATTR trialPharmaceutical Technology
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1GlobeNewswire
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureGlobeNewswire
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did BridgeBio Pharma Inc (BBIO) stock go up recently?▾
BridgeBio Pharma Inc (BBIO) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 124.07% to 124.58% on 2026-07-13. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-07-17, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 123.33%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-07-17, when analysts adjusted the next-year EPS growth estimate from 124.58% to 123.33%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.